NasdaqGS:LEGNBiotechs
Legend Biotech (LEGN) Q4 Loss Narrows To US$30.9m Testing Bullish Profitability Narrative
Legend Biotech (LEGN) has wrapped up FY 2025 with fourth quarter revenue of US$306.3 million and a basic EPS loss of US$0.17, alongside net income excluding extra items showing a loss of US$30.9 million. Trailing twelve month revenue reached about US$1.0 billion and EPS on this basis was a loss of US$1.61. The company has seen quarterly revenue move from US$186.5 million in Q4 2024 to US$306.3 million in Q4 2025, with quarterly basic EPS shifting from a profit of US$0.14 to a loss of US$0.17...